USA - NASDAQ:KRYS - US5011471027 - Common Stock
We assign a fundamental rating of 6 out of 10 to KRYS. KRYS was compared to 534 industry peers in the Biotechnology industry. While KRYS has a great health rating, its profitability is only average at the moment. A decent growth rate in combination with a cheap valuation! Better keep an eye on KRYS. These ratings could make KRYS a good candidate for value investing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 12.89% | ||
ROE | 14.1% | ||
ROIC | 12.87% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 42.26% | ||
PM (TTM) | 40.85% | ||
GM | 93.37% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 36.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 9.68 | ||
Quick Ratio | 9.33 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 39.06 | ||
Fwd PE | 24.53 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 29.99 | ||
EV/EBITDA | 29.71 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:KRYS (10/21/2025, 11:31:10 AM)
192.16
-3.8 (-1.94%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 39.06 | ||
Fwd PE | 24.53 | ||
P/S | 15.48 | ||
P/FCF | 29.99 | ||
P/OCF | 28.46 | ||
P/B | 5.34 | ||
P/tB | 5.34 | ||
EV/EBITDA | 29.71 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 12.89% | ||
ROE | 14.1% | ||
ROCE | 14.44% | ||
ROIC | 12.87% | ||
ROICexc | 36.62% | ||
ROICexgc | 36.62% | ||
OM | 42.26% | ||
PM (TTM) | 40.85% | ||
GM | 93.37% | ||
FCFM | 51.63% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 195.35% | ||
Cap/Sales | 2.77% | ||
Interest Coverage | 250 | ||
Cash Conversion | 124.54% | ||
Profit Quality | 126.39% | ||
Current Ratio | 9.68 | ||
Quick Ratio | 9.33 | ||
Altman-Z | 36.23 |